Galmed Pharmaceuticals Ltd.
GLMD
$4.63
$0.8121.05%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 45.18% | -27.70% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 35.76% | -32.81% | |||
| Operating Income | -35.76% | 32.81% | |||
| Income Before Tax | -42.57% | 60.36% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -42.57% | 60.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -42.57% | 60.36% | |||
| EBIT | -35.76% | 32.81% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -23.36% | 63.82% | |||
| Normalized Basic EPS | -23.37% | 37.59% | |||
| EPS Diluted | -23.36% | 63.82% | |||
| Normalized Diluted EPS | -23.37% | 37.59% | |||
| Average Basic Shares Outstanding | 15.57% | 9.58% | |||
| Average Diluted Shares Outstanding | 15.57% | 9.58% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||